A primer on heme biosynthesis
Author:
Dailey Harry A.12, Medlock Amy E.13ORCID
Affiliation:
1. Department of Biochemistry and Molecular Biology , University of Georgia , Athens , GA 30602-1111 , USA 2. Department of Microbiology , University of Georgia , Athens , GA 30602-1111 , USA 3. Augusta University/University of Georgia Medical Partnership, University of Georgia , Athens , GA , USA
Abstract
Abstract
Heme (protoheme IX) is an essential cofactor for a large variety of proteins whose functions vary from one electron reactions to binding gases. While not ubiquitous, heme is found in the great majority of known life forms. Unlike most cofactors that are acquired from dietary sources, the vast majority of organisms that utilize heme possess a complete pathway to synthesize the compound. Indeed, dietary heme is most frequently utilized as an iron source and not as a source of heme. In Nature there are now known to exist three pathways to synthesize heme. These are the siroheme dependent (SHD) pathway which is the most ancient, but least common of the three; the coproporphyrin dependent (CPD) pathway which with one known exception is found only in gram positive bacteria; and the protoporphyrin dependent (PPD) pathway which is found in gram negative bacteria and all eukaryotes. All three pathways share a core set of enzymes to convert the first committed intermediate, 5-aminolevulinate (ALA) into uroporphyrinogen III. In the current review all three pathways are reviewed as well as the two known pathways to synthesize ALA. In addition, interesting features of some heme biosynthesis enzymes are discussed as are the regulation and disorders of heme biosynthesis.
Publisher
Walter de Gruyter GmbH
Subject
Clinical Biochemistry,Molecular Biology,Biochemistry
Reference163 articles.
1. Agostinis, P., Berg, K., Cengel, K.A., Foster, T.H., Girotti, A.W., Gollnick, S.O., Hahn, S.M., Hamblin, M.R., Juzeniene, A., Kessel, D., et al.. (2011). Photodynamic therapy of cancer: an update. Ca – Cancer J. Clin. 61: 250–281, https://doi.org/10.3322/caac.20114. 2. Al-Karadaghi, S., Hansson, M., Nikonov, S., Jonsson, B., and Hederstedt, L. (1997). Crystal structure of ferrochelatase: the terminal enzyme in heme biosynthesis. Structure 5: 1501–1510, https://doi.org/10.1016/s0969-2126(97)00299-2. 3. Astner, I., Schulze, J.O., van den Heuvel, J., Jahn, D., Schubert, W.D., and Heinz, D.W. (2005). Crystal structure of 5-aminolevulinate synthase, the first enzyme of heme biosynthesis, and its link to XLSA in humans. EMBO J. 24: 3166–3177, https://doi.org/10.1038/sj.emboj.7600792. 4. Bai, Y., Kim, J.Y., Bisunke, B., Jayne, L.A., Silvaroli, J.A., Balzer, M.S., Gandhi, M., Huang, K.M., Sander, V., Prosek, J., et al.. (2021). Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition. Kidney Int. 100: 1214–1226, https://doi.org/10.1016/j.kint.2021.08.022. 5. Bailey, H.J., Bezerra, G.A., Marcero, J.R., Padhi, S., Foster, W.R., Rembeza, E., Roy, A., Bishop, D.F., Desnick, R.J., Bulusu, G., et al.. (2020). Human aminolevulinate synthase structure reveals a eukaryotic-specific autoinhibitory loop regulating substrate binding and product release. Nat. Commun. 11: 2813, https://doi.org/10.1038/s41467-020-16586-x.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|